78
Views
3
CrossRef citations to date
0
Altmetric
Review

A Schlemm’s canal scaffold for the treatment of elevated IOP

, &
Pages 259-266 | Received 18 Mar 2016, Accepted 04 Jul 2016, Published online: 20 Jul 2016

References

  • Quigley HA. Glaucoma. Lancet. 2011;377(9774):1367–1377.
  • Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol. 2012;96(5):614–618.
  • Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–2090.
  • Kapetanakis VV, Chan MP, Foster PJ, et al. Global variations and time trends in the prevalence of primary open angle glaucoma (POAG): a systematic review and metaanalysis. Br J Ophthalmol. 2016;100(1):86–93.
  • Braunger BM, Fuchshofer R, Tamm ER. The aqueous humor outflow pathways in glaucoma: a unifying concept of disease mechanisms and causative treatment. Eur J Pharm Biopharm. 2015;95(Pt B):173–181.
  • Sommer A, Tielsch JM, Katz J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol. 1991;109(8):1090–1095.
  • Rulli E, Biagioli E, Riva I, et al. Efficacy and safety of trabeculectomy vs nonpenetrating surgical procedures: a systematic review and meta-analysis. JAMA Ophthalmol. 2013;131(12):1573–1582.
  • Razeghinejad MR, Fudemberg SJ, Spaeth GL. The changing conceptual basis of trabeculectomy: a review of past and current surgical techniques. Surv Ophthalmol. 2012;57(1):1–25.
  • Cholkar K, Trinh HM, Pal D, et al. Discovery of novel inhibitors for the treatment of glaucoma. Expert Opin Drug Discov. 2015;10(3):293–313.
  • Schmidl D, Schmetterer L, Garhofer G, et al. Pharmacotherapy of glaucoma. J Ocul Pharmacol Ther. 2015;31(2):63–77.
  • Sun Y, Williams A, Waisbourd M, et al. Stem cell therapy for glaucoma: science or snake oil? Surv Ophthalmol. 2015;60(2):93–105.
  • Rasmussen CA, Kaufman PL. Exciting directions in glaucoma. Can J Ophthalmol. 2014;49(6):534543.
  • Tsai JC. Medication adherence in glaucoma: approaches for optimizing patient compliance. Curr Opin Ophthalmol. 2006;17(2):190–195.
  • Broadway DC, Cate H. Pharmacotherapy and adherence issues in treating elderly patients with glaucoma. Drugs Aging. 2015;32(7):569–581.
  • SooHoo JR, Seibold LK, Radcliffe NM, et al. Minimally invasive glaucoma surgery: current implants and future innovations. Can J Ophthalmol. 2014;49(6):528–533.
  • Ahmed II. MIGS and the FDA: what’s in a name? Ophthalmology. 2015;122(9):1737–1739.
  • Saheb H, Ahmed II. Micro-invasive glaucoma surgery: current perspectives and future directions. Curr Opin Ophthalmol. 2012;23(2):96–104.
  • Sacca SC, Gandolfi S, Bagnis A, et al. The outflow pathway: a tissue with morphological and functional unity. J Cell Physiol. 2016;231:1876–1893.
  • Aspelund A, Tammela T, Antila S, et al. The Schlemm’s canal is a VEGF-C/VEGFR-3-responsive lymphatic-like vessel. J Clin Invest. 2014;124(9):3975–3986.
  • Dautriche CN, Tian Y, Xie Y, et al. A closer look at Schlemm’s canal cell physiology: implications for biomimetics. J Funct Biomater. 2015;6(3):963–985.
  • Karpinich NO, Caron KM. Schlemm’s canal: more than meets the eye, lymphatics in disguise. J Clin Invest. 2014;124(9):3701–3703.
  • Robinson R. Unique origin of eye canal combines elements of blood, lymph tube development. PLoS Biol. 2014;12(7):e1001913.
  • Johnstone MA, Grant WG. Pressure-dependent changes in structures of the aqueous outflow system of human and monkey eyes. Am J Ophthalmol. 1973;75(3):365–383.
  • Li G, Farsiu S, Chiu SJ, et al. Pilocarpine-induced dilation of Schlemm’s canal and prevention of lumen collapse at elevated intraocular pressures in living mice visualized by OCT. Invest Ophthalmol Vis Sci. 2014;55(6):3737–3746.
  • Battista SA, Lu Z, Hofmann S, et al. Reduction of the available area for aqueous humor outflow and increase in meshwork herniations into collector channels following acute IOP elevation in bovine eyes. Invest Ophthalmol Vis Sci. 2008;49(12):5346–5352.
  • Stegmann R, Pienaar A, Miller D. Viscocanalostomy for open-angle glaucoma in black African patients. J Cataract Refract Surg. 1999;25(3):316–322.
  • Grieshaber MC, Peckar C, Pienaar A, et al. Long-term results of up to 12 years of over 700 cases of viscocanalostomy for open-angle glaucoma. Acta Ophthalmol. 2015;93(4):362–367.
  • Mansouri K, Shaarawy T. Update on Schlemm’s canal based procedures. Middle East Afr J Ophthalmol. 2015;22(1):38–44.
  • Khaimi MA. Canaloplasty: a minimally invasive and maximally effective glaucoma treatment. J Ophthalmol. 2015;2015:485065.
  • Grieshaber MC, Stegmann R, Grieshaber HR, et al. Novel device for expanding Schlemm’s canal: a morphological study: Implantation of the Stegmann Canal Expander following viscodilation of Schlemm’s canal resulted in permanent expansion of the canal lumen and distension of the trabecular meshwork without complications. Br J Ophthalmol. 2015;99(7):875–877.
  • Castleman LS, Motzkin SM, Alicandri FP, et al. Biocompatibility of nitinol alloy as an implant material. J Biomed Mater Res. 1976;10(5):695–731.
  • Lavy J, Khalil S. Five-year hearing results with the shape memory nitinol stapes prosthesis. Laryngoscope. 2014;124(11):2591–2593.
  • Roosli C, Schmid P, Huber AM. Biocompatibility of nitinol stapes prosthesis. Otol Neurotol. 2011;32(2):265–270.
  • Marmagkiolis K, Hakeem A, Choksi N, et al. 12-Month primary patency rates of contemporary endovascular device therapy for femoro-popliteal occlusive disease in 6,024 patients: beyond balloon angioplasty. Catheter Cardiovasc Interv. 2014;84(4):555–564.
  • Shayan M, Chun Y. An overview of thin film nitinol endovascular devices. Acta Biomater. 2015;21:20–34.
  • Porpiglia F, Fiori C, Bertolo R, et al. Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up. BJU Int. 2015;116(2):278–287.
  • Aiyer A, Russell NA, Pelletier MH, et al. The impact of nitinol staples on the compressive forces, contact area, and mechanical properties in comparison to a claw plate and crossed screws for the first tarsometatarsal arthrodesis. Foot Ankle Spec. 2016;9(3):232–240.
  • Nespoli A, Dallolio V, Villa E, et al. A new design of a nitinol ring-like wire for suturing in deep surgical field. Mater Sci Eng C Mater Biol Appl. 2015;56:30–36.
  • Assad M, Chernyshov A, Leroux MA, et al. A new porous titanium-nickel alloy: part 1. cytotoxicity and genotoxicity evaluation. Biomed Mater Eng. 2002;12(3):225–237.
  • Haider W, Munroe N. Assessment of corrosion resistance and metal ion leaching of nitinol alloys. J Mater Eng Perform. 2011;20(4):812–815.
  • Henderson E, Nash DH, Dempster WM. On the experimental testing of fine nitinol wires for medical devices. J Mech Behav Biomed Mater. 2011;4(3):261–268.
  • Shabalovskaya SA. Surface, corrosion and biocompatibility aspects of nitinol as an implant material. Biomed Mater Eng. 2002;12(1):69–109.
  • Olson JL, Velez-Montoya R, Erlanger M. Ocular biocompatibility of nitinol intraocular clips. Invest Ophthalmol Vis Sci. 2012;53(1):354–360.
  • Grierson I, Saheb H, Kahook MY, et al. A novel Schlemm’s canal scaffold: histologic observations. JGlaucoma. 2015;24(6):460–468.
  • Shabalovskaya S, Anderegg J, Van Humbeeck J. Critical overview of nitinol surfaces and their modifications for medical applications. Acta Biomater. 2008;4(3):447–467.
  • Shabalovskaya SA, Tian H, Anderegg JW, et al. The influence of surface oxides on the distribution and release of nickel from nitinol wires. Biomaterials. 2009;30(4):468–477.
  • Camras LJ, Yuan F, Fan S, et al. A novel Schlemm’s canal scaffold increases outflow facility in a human anterior segment perfusion model. Invest Ophthalmol Vis Sci. 2012;53(10):6115–6121.
  • Gulati V, Fan S, Hays CL, et al. A novel 8-mm Schlemm’s canal scaffold reduces outflow resistance in a human anterior segment perfusion model. Invest Ophthalmol Vis Sci. 2013;54(3):1698–1704.
  • Johnstone MA, Saheb H, Ahmed II, et al. Effects of a Schlemm’ canal scaffold on collector channel ostia in human anterior segments. Exp Eye Res. 2014;119:70–76.
  • Smit BA, Johnstone MA. Effects of viscoelastic injection into Schlemm’s canal in primate and human eyes: potential relevance to viscocanalostomy. Ophthalmology. 2002;109(4):786–792.
  • Yuan F, Schieber AT, Camras LJ, et al. Mathematical modeling of outflow facility increase with trabecular meshwork bypass and Schlemm canal dilation. J Glaucoma. 2016;25(4):355–364.
  • FDA approves first glaucoma stent for use with cataract surgery. [updated 2012]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm309667.htm
  • Wellik SR, Dale EA. A review of the iStent((R)) trabecular micro-bypass stent: safety and efficacy. Clin Ophthalmol. 2015;9:677–684.
  • Hays CL, Gulati V, Fan S, et al. Improvement in outflow facility by two novel microinvasive glaucoma surgery implants. Invest Ophthalmol Vis Sci. 2014;55(3):1893–1900.
  • Gong H, Cha E, Gorantla V, et al. Characterization of aqueous humor outflow through novel glaucoma devices – A tracer study. Invest Ophthalmol Vis Sci. 2012;53:3743.
  • Sameulson T, Tetz M, Pfeiffer N, et al. One year results of an intracanalicular microstent for IOP reduction in open angle glaucoma. 117th Annual meeting of the American Academy of Ophthalmology; 2012 Nov; Chicago, IL.
  • Tetz M, Pfeiffer N, Ramirez M, et al. 12 Month results from a prospective multicenter study of nickel titanium Schlemm’s canal microstent for IOP reduction after cataract surgery in open angle glaucoma. In: 30th Congress of European Society of Cataract and Refractive Surgery; 2012 Sep; Milan, Italy.
  • Pfeiffer N, Garcia-Feijoo J, Martinez-de-la-Casa JM, et al. A randomized trial of a Schlemm’s canal microstent with phacoemulsification for reducing intraocular pressure in open-angle glaucoma. Ophthalmology. 2015;122(7):1283–1293.
  • American national standards institute. ANSI Z80.27 Ophthalmics: Implantable Glaucoma Devices. Available from: http://webstore.ansi.org/RecordDetail.aspx?sku=ANSI%20Z80.27-2014
  • Fea AM, Consolandi G, Pignata G, et al. A comparison of endothelial cell loss in combined cataract and MIGS (Hydrus) procedure to phacoemulsification alone: 6-month results. J Ophthalmol. 2015;2015:769289.
  • Hau S, Barton K. Corneal complications of glaucoma surgery. Curr Opin Ophthalmol. 2009;20(2):131–136.
  • Lee EK, Yun YJ, Lee JE, et al. Changes in corneal endothelial cells after ahmed glaucoma valve implantation: 2-year follow-up. Am J Ophthalmol. 2009;148(3):361–367.
  • Seo JW, Lee JY, Nam DH, et al. Comparison of the changes in corneal endothelial cells after pars plana and anterior chamber ahmed valve implant. J Ophthalmol. 2015;2015:486832.
  • Ike K, Ahmed M. Intracanalicular scaffold for IOP reduction with cataract surgery in mild to moderate open angle glaucoma. [updated 2012]. Available from: http://www.ivantisinc.com/pdf/Ahmed%20HYDRUS%20Combo%20series%20ASCRS%202012.pdf
  • Ahmed IK. Compare the hydrus microstent(TM) to the iStent for lowering IOP in glaucoma patients having cataract surgery (hydrus III). Available from: https://clinicaltrials.gov/ct2/show/NCT02024464
  • Ivantis completes enrollment in pivotal HYDRUS IV glaucoma study of the hydrus™ microstent. [updated 2015 Apr 17]. Available from: http://www.reuters.com/article/ca-ivantis-inc-idUSnBw175128a±100±BSW20150417
  • Alan Crandall M. Safety & effectiveness study of the Hydrus device for lowering IOP in glaucoma patients undergoing cataract surgery. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01539239?show_locs=Y#locn
  • Comparing effectiveness of the Hydrus microstent (TM) to two iStents to lower IOP in phakic eyes (Hydrus V). Available from: https://clinicaltrials.gov/ct2/show/NCT02023242
  • Zhou J, Smedley GT. Trabecular bypass: effect of Schlemm canal and collector channel dilation. JGlaucoma. 2006;15(5):446–455.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.